nach oben

Erschienen in:

16.06.2020 | Review Article

Current application of cannabidiol (CBD) in the management and treatment of neurological disorders

verfasst von: Brian Fiani, Kasra John Sarhadi, Marisol Soula, Atif Zafar, Syed A. Quadri

Erschienen in: Neurological Sciences | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Cannabidiol (CBD), which is nonintoxicating pharmacologically relevant constituents of Cannabis, demonstrates several beneficial effects. It has been found to have antioxidative, anti-inflammatory, and neuroprotective effects. As the medicinal use of CBD is gaining popularity for treatment of various disorders, the recent flare-up of largely unproven and unregulated cannabis-based preparations on medical therapeutics may have its greatest impact in the field of neurology. Currently, as lot of clinical trials are underway, CBD demonstrates remarkable potential to become a supplemental therapy in various neurological conditions. It has shown promise in the treatment of neurological disorders such as anxiety, chronic pain, trigeminal neuralgia, epilepsy, and essential tremors as well as psychiatric disorders. While recent FDA-approved prescription drugs have demonstrated safety, efficacy, and consistency enough for regulatory approval in spasticity in multiple sclerosis (MS) and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges still remain. In the current review, the authors have shed light on the application of CBD in the management and treatment of various neurological disorders.

Volkow ND, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 371(9):878–879. https://doi.org/10.1056/NEJMc1407928CrossRef

Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 73(3):292–297. https://doi.org/10.1001/jamapsychiatry.2015.3278CrossRefPubMed

Jamil M, Zafar A, Adeel Faizi S, Zawar I (2016) Stroke from vasospasm due to marijuana use: can cannabis synergistically with other medications trigger cerebral vasospasm? Case Rep Neurol Med 2016:5313795–5313794. https://doi.org/10.1155/2016/5313795CrossRefPubMedPubMedCentral

Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a cannabis sativa constituent. Curr Drug Saf 6(4):237–249. https://doi.org/10.2174/157488611798280924CrossRefPubMed

Grotenhermen F, Müller-Vahl K (2016) Cannabis und cannabinoide in der medizin: fakten und ausblick. Suchttherapie 17(02):71–76. https://doi.org/10.1055/s-0042-100702CrossRef

Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (−)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95(14):8268–8273. https://doi.org/10.1073/pnas.95.14.8268CrossRefPubMedPubMedCentral

Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, Pál B, Ambrus L, Kloepper J, Camera E, Ludovici M, Picardo M, Voets T, Zouboulis CC, Paus R, Bíró T (2014) Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Investig 124(9):3713–3724. https://doi.org/10.1172/jci64628CrossRefPubMedPubMedCentral

Mikuriya TH (1969) Marijuana in medicine: past, present and future. Calif Med 110(1):34–40PubMedPubMedCentral

Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M (2017) Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther 175:133–150. https://doi.org/10.1016/j.pharmthera.2017.02.041CrossRefPubMed

10.

Mechoulam R, Shvo Y (1963) Hashish—I: the structure of cannabidiol. Tetrahedron 19(12):2073–2078CrossRefPubMed

11.

Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009) Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res 23(5):597–602. https://doi.org/10.1002/ptr.2625CrossRefPubMed

12.

Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, Hinz B (2013) COX-2 and PPAR-gamma confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther 12(1):69–82. https://doi.org/10.1158/1535-7163.MCT-12-0335CrossRefPubMed

13.

Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74(2):129–180CrossRefPubMed

14.

Lunn CA, Reich EP, Bober L (2006) Targeting the CB2 receptor for immune modulation. Expert Opin Ther Targets 10(5):653–663. https://doi.org/10.1517/14728222.10.5.653CrossRefPubMed

15.

Veronesi B, Oortgiesen M (2006) The TRPV1 receptor: target of toxicants and therapeutics. Toxicol Sci 89(1):1–3. https://doi.org/10.1093/toxsci/kfj034CrossRefPubMed

16.

Pazos MR, Mohammed N, Lafuente H, Santos M, Martinez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martinez-Orgado J (2013) Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology 71:282–291. https://doi.org/10.1016/j.neuropharm.2013.03.027CrossRefPubMed

17.

Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA (2008) The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology 196(3):389–395. https://doi.org/10.1007/s00213-007-0970-1CrossRefPubMed

18.

Soares Vde P, Campos AC, Bortoli VC, Zangrossi H Jr, Guimaraes FS, Zuardi AW (2010) Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res 213(2):225–229. https://doi.org/10.1016/j.bbr.2010.05.004CrossRefPubMed

19.

Chen JW, Borgelt LM, Blackmer AB (2019) Cannabidiol: a new hope for patients with Dravet or Lennox-Gastaut syndromes. Ann Pharmacother 53(6):603–611. https://doi.org/10.1177/1060028018822124CrossRefPubMed

20.

Samara E, Bialer M, Harvey DJ (1990) Pharmacokinetics of urinary metabolites of cannabidiol in the dog. Biopharm Drug Dispos 11(9):785–795CrossRefPubMed

21.

Wang T, Collet JP, Shapiro S, Ware MA (2008) Adverse effects of medical cannabinoids: a systematic review. CMAJ 178(13):1669–1678. https://doi.org/10.1503/cmaj.071178CrossRefPubMedPubMedCentral

22.

Mead A (2016) The legal and regulatory status of cannabidiol (CBD). Planta Med 82(05). https://doi.org/10.1055/s-0036-1578585

23.

Mead A (2017) The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav 70(Pt B):288–291. https://doi.org/10.1016/j.yebeh.2016.11.021CrossRefPubMed

24.

Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O (2019) An update of current cannabis-based pharmaceuticals in pain medicine. Pain Ther 8(1):41–51. https://doi.org/10.1007/s40122-019-0114-4CrossRefPubMedPubMedCentral

25.

Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D (2007) Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133(1–3):210–220. https://doi.org/10.1016/j.pain.2007.08.028CrossRefPubMed

26.

CADTH rapid response reports (2016) Cannabinoid buccal spray for chronic non-cancer or neuropathic pain: a review of clinical effectiveness, safety, and guidelines. In: CADTH Rapid Response Reports. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)

27.

Blake DR, Robson P, Ho M, Jubb RW, McCabe CS (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45(1):50–52. https://doi.org/10.1093/rheumatology/kei183CrossRef

28.

Arjmand S, Vaziri Z, Behzadi M, Abbassian H, Stephens GJ, Shabani M (2015) Cannabinoids and tremor induced by motor-related disorders: friend or foe? Neurotherapeutics 12(4):778–787. https://doi.org/10.1007/s13311-015-0367-5CrossRefPubMedPubMedCentral

29.

Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ (2015) Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12(4):699–730. https://doi.org/10.1007/s13311-015-0377-3CrossRefPubMedPubMedCentral

30.

Abbassian H, Whalley BJ, Sheibani V, Shabani M (2016) Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat. Br J Pharmacol 173(22):3196–3207. https://doi.org/10.1111/bph.13581CrossRefPubMedPubMedCentral

31.

Kolasiewicz W, Kuter K, Wardas J, Ossowska K (2009) Role of the metabotropic glutamate receptor subtype 1 in the harmaline-induced tremor in rats. J Neural Transm (Vienna) 116(9):1059–1063. https://doi.org/10.1007/s00702-009-0254-5CrossRef

32.

Handforth A (2012) Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor. Tremor Other Hyperkinet Mov (N Y) 2. https://doi.org/10.7916/D8TD9W2P

33.

Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L (2009) Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther 15(1):65–75. https://doi.org/10.1111/j.1755-5949.2008.00065.xCrossRefPubMedPubMedCentral

34.

Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19(1–2):96–107. https://doi.org/10.1016/j.nbd.2004.11.009CrossRefPubMed

35.

Devinsky O, Marsh E, Friedman D (2016) Cannabidiol in patients with treatment-resistant epilepsy - Authors' reply. Lancet Neurol 15(6):545–546. https://doi.org/10.1016/S1474-4422(16)00120-4CrossRefPubMed

36.

Laurie K Mischley N (2019) Cannabis and Parkinson's disease tremor: a natural history study. https://clinicaltrials.gov/ct2/show/NCT02028858

37.

Blessing EM, Steenkamp MM, Manzanares J, Marmar CR (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12(4):825–836. https://doi.org/10.1007/s13311-015-0387-1CrossRefPubMedPubMedCentral

38.

Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 76(3):245–250CrossRefPubMed

39.

Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS (1993) Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 7(1 Suppl):82–88. https://doi.org/10.1177/026988119300700112CrossRefPubMed

40.

McDonough P, McKenna JP, McCreary C, Downer EJ (2014) Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. Int J Biochem Cell Biol 55:72–78. https://doi.org/10.1016/j.biocel.2014.08.007CrossRefPubMed

41.

Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA (2014) Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series. J Clin Pharm Ther 39(5):564–566. https://doi.org/10.1111/jcpt.12179CrossRefPubMed

42.

Consroe P, Musty R, Rein J, Tillery W, Pertwee R (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38(1):44–48. https://doi.org/10.1159/000112901CrossRefPubMed

43.

Elliott J, McCoy B, Clifford T, Potter BK, Skidmore B, Wells GA, Coyle D (2019) Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. Syst Rev 8(1):75. https://doi.org/10.1186/s13643-019-0990-zCrossRefPubMedPubMedCentral

44.

Liang YC, Huang CC, Hsu KS (2007) The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. Neuropharmacology 53(1):169–177. https://doi.org/10.1016/j.neuropharm.2007.04.019CrossRefPubMed

45.

Harold Merskey D (1994) Classification of chronic pain: description of chronic pain syndromes and definitions of pain terms, 2nd edn. IASP PRESS, Seattle

46.

Mondello E, Quattrone D, Cardia L, Bova G, Mallamace R, Barbagallo AA, Mondello C, Mannucci C, Di Pietro M, Arcoraci V, Calapai G (2018) Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain. J Pain Res 11:1761–1767. https://doi.org/10.2147/JPR.S166617CrossRefPubMedPubMedCentral

47.

Peul WC, van Houwelingen HC, van den Hout WB, Brand R, Eekhof JA, Tans JT, Thomeer RT, Koes BW, Leiden-The Hague Spine Intervention Prognostic Study G (2007) Surgery versus prolonged conservative treatment for sciatica. N Engl J Med 356(22):2245–2256. https://doi.org/10.1056/NEJMoa064039CrossRefPubMed

48.

Compston A, Coles A (2002) Multiple sclerosis. Lancet 359(9313):1221–1231. https://doi.org/10.1016/S0140-6736(02)08220-XCrossRefPubMed

49.

Perras C (2005) Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 72:1–4

50.

Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D (2014) Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 82(17):1556–1563. https://doi.org/10.1212/WNL.0000000000000363CrossRefPubMedPubMedCentral

51.

Consroe P, Kennedy K, Schram K (1991) Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav 40(3):517–522CrossRefPubMed

52.

Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R (2015) Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav 47:138–141. https://doi.org/10.1016/j.yebeh.2015.04.009CrossRefPubMed

53.

Kurz R, Blaas K (2010) Use of dronabinol (delta-9-THC) in autism: a prospective single-case-study with an early infantile autistic child. Cannabinoids 5(4):4–6

54.

Fernandez-Lopez D, Lizasoain I, Moro MA, Martinez-Orgado J (2013) Cannabinoids: well-suited candidates for the treatment of perinatal brain injury. Brain Sci 3(3):1043–1059. https://doi.org/10.3390/brainsci3031043CrossRefPubMedPubMedCentral

55.

Fisher T, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R, Mechoulam R, Toren A (2016) In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol 23(2):S15–S22. https://doi.org/10.3747/co.23.2893CrossRefPubMedPubMedCentral

56.

Burns HD, Van Laere K, Sanabria-Bohorquez S, Hamill TG, Bormans G, Eng WS, Gibson R, Ryan C, Connolly B, Patel S, Krause S, Vanko A, Van Hecken A, Dupont P, De Lepeleire I, Rothenberg P, Stoch SA, Cote J, Hagmann WK, Jewell JP, Lin LS, Liu P, Goulet MT, Gottesdiener K, Wagner JA, de Hoon J, Mortelmans L, Fong TM, Hargreaves RJ (2007) [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104(23):9800–9805. https://doi.org/10.1073/pnas.0703472104CrossRefPubMedPubMedCentral

57.

Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, Alati R, Bor W (2007) Cannabis and anxiety and depression in young adults: a large prospective study. J Am Acad Child Adolesc Psychiatry 46(3):408–417. https://doi.org/10.1097/chi.0b013e31802dc54dCrossRefPubMed

58.

Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL (2011) Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry 198(6):442–447. https://doi.org/10.1192/bjp.bp.110.077479CrossRefPubMed

59.

Batalla A, Janssen H, Gangadin SS, Bossong MG (2019) The potential of Cannabidiol as a treatment for psychosis and addiction: who benefits Most? A systematic review. J Clin Med 8(7). https://doi.org/10.3390/jcm8071058

60.

Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, McGuire PK, Guimaraes FS (2012) A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des 18(32):5131–5140. https://doi.org/10.2174/138161212802884681CrossRefPubMed

61.

Walther S, Halpern M (2010) Cannabinoids and dementia: a review of clinical and preclinical data. Pharmaceuticals 3(8):2689–2708. https://doi.org/10.3390/ph3082689CrossRefPubMedPubMedCentral

Titel: Current application of cannabidiol (CBD) in the management and treatment of neurological disorders
verfasst von: Brian Fiani
Kasra John Sarhadi
Marisol Soula
Atif Zafar
Syed A. Quadri
Publikationsdatum: 16.06.2020
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 11/2020
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04514-2

Kompaktes Leitlinien-Wissen Neurologie

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Eskalieren der MS-Therapie ab zwei neuen T2-Läsionen lohnt sich

05.09.2024 Multiple Sklerose Nachrichten

MS-Kranke unter niedrig bis moderat wirksamen Therapien profitieren offenbar von einer Therapieeskalation, sobald zwei bis drei neue T2-Läsionen in der Kontroll-MRT auftreten. Das Risiko für weitere Schübe und eine Behinderungsprogression wird dann erheblich gesenkt.

Erste Hinweise: Aminosäure bremst frühen M. Parkinson

05.09.2024 Parkinson-Krankheit Nachrichten

Überraschendes Ergebnis bei zwei Personen mit REM-Schlafverhaltensstörungen (RBD): Eine Therapie mit Acetyl-DL-Leucin konnte die Parkinson-typische Neurodegeneration weitgehend stoppen. Zum Teil normalisierten sich Biomarker wie DAT-SPECT wieder, auch die RBD verschwand.

Neuro-Post-Covid persistiert oft länger als ein Jahr

30.08.2024 Post-COVID Nachrichten

Entwickeln Covidkranke autonome und immunologische Veränderungen, können diese lange anhalten: In einer Studie mit gründlich untersuchten Neuro-Post-Covid-Kranken waren über 70% der Abweichungen auch noch ein Jahr später nachweisbar.

Herzinfarkt beim Ehemann – erhöhtes Demenzrisiko bei der Partnerin

30.08.2024 Demenz Nachrichten

Erleidet der Ehemann einen Herzinfarkt oder Schlaganfall, ist das Demenzrisiko bei der Ehefrau um etwa ein Drittel erhöht. Darauf deutet eine Analyse von Versicherungsdaten aus Japan.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2020

The relationship of leukoaraiosis, haemorrhagic transformation and prognosis at 3 months after intravenous thrombolysis in elderly patients aged ≥ 60 years with acute cerebral infarction

Muscle echo intensity of abdominal wall in Parkinson’s disease and healthy controls: a cross sectional study

Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study

Predictive role of gnathological techniques for the treatment of persistent idiopathic facial pain (PIFP)